GoldenGolden
Emergent BioSolutions

Emergent BioSolutions

A life sciences company with a focus on biotechnology and vaccines. It was founded in 1998 and is located in Gaithersburg, Maryland.

Emergent BioSolutions is a Maryland-based biotechnology company that develops and manufactures healthcare solutions. It manufactures products, platforms, and other technologies to address public health threats. Its therapies have been used in the past for illnesses such as anthrax and botulism.

COVID-19

In 2020, Emergent BioSolutions partnered with Vaxart, a biotechnology company, to aid with developing and manufacturing Vaxart’s experimental oral vaccine candidate for COVID-19. The company is expected to produce a bulk quantity of the vaccine so that Vaxart can initiate its pre-clinical studies.

Emergent BioSolutions also partnered with Novavax, Inc. to develop and manufacture a COVID-19 vaccine candidate. According to the press release announcing the collaboration, announced in mid-March 2020, "Emergent will produce the COVID-19 experimental vaccine candidate, which is based on the proprietary recombinant protein nanoparticle technology platform of Novavax and utilizing their proprietary Matrix-M™ adjuvant to enhance immune responses. Emergent has initiated work for this program anticipating that the COVID-19 experimental vaccine candidate will be used in a Phase 1 clinical study within the next four months."

Emergent BioSolutions has partnered with the US government to expedite the development of a plasma-derived therapy, COVID-Human Immune Globulin (COVID-HIG) for severe hospitalized and high-risk patients to prevent progression to severe symptoms. The company received $14.5 million form BARDA in support of the program. COVID-HIG is a candidate human hyperimmune product, polyclonal antibody therapeutics, that will be manufactured using plasma donated from people who recovered from COVID-19 and have antibodies to SARS-CoV-2.

Timeline

April 3, 2020
Emergent BioSolutions raises a $14,500,000 grant from Biomedical Advanced Research and Development Authority.
September 25, 2019
Emergent BioSolutions raises a $20,000,000 grant.

Funding rounds

People

Name
Role
LinkedIn

Bob Kramer

CEO

Further reading

Title
Author
Link
Type
Date

Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease | Emergent BioSolutions Inc.

Emergent BioSolutions

Web

March 10, 2020

Emergent Biosolutions, Inc. (NYSE:EBS), Novavax, Inc. (NASDAQ:NVAX) - Emergent BioSolutions CEO Talks ...

Jayson Derrick

Web

March 12, 2020

Vaxart Announces It Entered Into An Agreement With Emergent Biosolutions For The Development And Manufacturing Of Oral Coronavirus (Covid-19) Vaccine Candidate

BioSpace

Web

March 18, 2020

Documentaries, videos and podcasts

Title
Date
Link

Emergent BioSolutions, Eyeing Two Plasma Therapies for Covid-19, Wins Fed's Help

April 5, 2020

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Rosen Law Firm, P.A.
June 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between...
Kahn Swick & Foti, LLC
June 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have...
Pomerantz LLP
June 16, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such...
Beth Mole
June 16, 2021
Ars Technica
More than 100 million vaccine doses are still in limbo at the facility.
Kessler Topaz Meltzer & Check, LLP
June 14, 2021
www.prnewswire.com:443
/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent...
June 12, 2021
The Economic Times
This is the latest in a series of setbacks for a company whose single-shot vaccine was once considered crucial to the US inoculation campaign.
By LINDA A. JOHNSON and ZEKE MILLER
June 11, 2021
AP NEWS
U.S. regulators are allowing the release of about 10 million doses of Johnson & Johnson's COVID-19 vaccine from a troubled Baltimore factory, but many more doses can't be used and must be thrown out.
Kelly McLaughlin,Madison Hall
June 11, 2021
news.yahoo.com
People familiar with the situation told The New York Times that the FDA will allow some other doses to be distributed, but with a warning attached.
Kessler Topaz Meltzer & Check, LLP
June 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent...
Rosen Law Firm, P.A.
June 5, 2021
www.prnewswire.com:443
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between...
Pomerantz LLP
June 1, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such...
Kessler Topaz Meltzer & Check, LLP
May 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action...
Alex Keown
May 26, 2021
BioSpace
Emergent said the vaccine candidate against the mosquito-borne illness showed an increase in immune response as measured by anti-chikungunya virus SNA.
May 26, 2021
BioSpace
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company's Chikungunya Virus Virus-Like Particle Vaccine Candidate - read this article along with other careers information, tips and advice on BioSpace
Law Offices of Howard G. Smith
May 20, 2021
www.prnewswire.com:443
/PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the case filed on...
Mark Terry
May 20, 2021
BioSpace
The House Select Subcommittee on the Coronavirus Crisis questioned executives from Emergent BioSolutions as part of a congressional probe.
Anna Cooban
May 20, 2021
Business Insider
In a five-week period, 40 Emergent BioSolutions staff entered the manufacturing area, and only three showers were documented, the FDA said.
Sheryl Gay Stolberg and Sharon LaFraniere
May 19, 2021
www.nytimes.com
Executives from Emergent, which ruined millions of coronavirus vaccine doses, divulged to Congress the scope of the regulatory review of its troubled Baltimore plant.
Beth Mole
May 19, 2021
Ars Technica
Tens of millions of J&J and AstraZeneca doses are still in limbo.
Sheryl Gay Stolberg and Sharon LaFraniere
May 19, 2021
www.nytimes.com
Executives from Emergent, which ruined millions of coronavirus vaccine doses, divulged to Congress the scope of the regulatory review of its troubled Baltimore plant.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.